Compare ARWR & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARWR | GKOS |
|---|---|---|
| Founded | 2003 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 8.7B |
| IPO Year | 2009 | 2015 |
| Metric | ARWR | GKOS |
|---|---|---|
| Price | $88.70 | $152.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 12 |
| Target Price | $83.40 | ★ $126.92 |
| AVG Volume (30 Days) | ★ 2.0M | 768.7K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 99.80 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $16,142,321.00 | ★ $507,442,000.00 |
| Revenue This Year | N/A | $23.32 |
| Revenue Next Year | N/A | $27.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.33 |
| 52 Week Low | $15.01 | $73.16 |
| 52 Week High | $87.83 | $161.53 |
| Indicator | ARWR | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 65.40 | 61.41 |
| Support Level | $70.03 | $96.44 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 4.40 | 6.07 |
| MACD | 0.06 | -0.46 |
| Stochastic Oscillator | 77.27 | 64.85 |
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.